List of Excipients in Branded Drug CYCLOBENZAPRINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	DIETHYL PHTHALATE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	ETHYLCELLULOSE
Direct_Rx	CYCLOBENZAPRINE HCL ER	cyclobenzaprine hcl er	72189-362	FD&C BLUE NO. 1

Generic Drugs Containing CYCLOBENZAPRINE

Company	Ingredient	NDC	Excipient
Macleods Pharmaceuticals Limited	cyclobenzaprine	33342-272	D&C YELLOW NO. 10
Macleods Pharmaceuticals Limited	cyclobenzaprine	33342-272	ETHYLCELLULOSE
Macleods Pharmaceuticals Limited	cyclobenzaprine	33342-272	FD&C GREEN NO. 3

What are the Most Frequently-Used Excipients in CYCLOBENZAPRINE?

# Of NDCs	Excipient
1	ANHYDROUS LACTOSE
5	CELLULOSE, MICROCRYSTALLINE
3	CROSCARMELLOSE SODIUM

Last updated: August 5, 2026

Cyclobenzaprine is a mature, genericized skeletal-muscle relaxant with limited composition-of-matter or conventional formulation patent leverage. Commercial opportunity is concentrated in dosage-form differentiation, adherence, patient convenience, controlled release, and cost-efficient excipient systems. The strongest near-term targets are orally disintegrating tablets, low-volume liquids, sprinkle capsules, and robust immediate-release tablets designed for high-volume generic supply.

Cyclobenzaprine Excipient Strategy and Commercial Opportunities

What is the commercial status of cyclobenzaprine?

Cyclobenzaprine hydrochloride is a centrally acting skeletal-muscle relaxant approved in the United States for short-term treatment of acute, painful musculoskeletal conditions. Immediate-release tablets were approved in the 1970s. Extended-release cyclobenzaprine capsules were later approved under the Amrix brand.

The product is now primarily a generic market. Immediate-release tablets are available in 5 mg and 10 mg strengths. Extended-release products have historically used a 15 mg and 30 mg strength structure, although commercial availability varies by manufacturer and market.

Product characteristic	Commercial position
Active ingredient	Cyclobenzaprine hydrochloride
Main dosage forms	Immediate-release tablets; extended-release capsules
Common strengths	5 mg and 10 mg immediate release
Primary use	Short-term treatment of acute musculoskeletal pain and spasm
Prescription status	Prescription-only in the United States
Generic status	Established generic market
Main regulatory route for new generics	Abbreviated New Drug Application
Main differentiation levers	Dosage form, swallowing convenience, release profile, packaging, supply reliability
Principal commercial constraint	Low unit pricing and limited clinical differentiation

Cyclobenzaprine has pharmacologic similarities to tricyclic antidepressants. The FDA label warns about anticholinergic effects, sedation, serotonin-related interactions, and contraindications involving monoamine oxidase inhibitors. These characteristics affect formulation design, labeling, patient selection, and the commercial value of adherence-oriented products.[1]

What excipients are used in cyclobenzaprine tablets and capsules?

Cyclobenzaprine products use conventional excipient systems. The exact composition varies by manufacturer, strength, coating process, and dosage form.

Immediate-release tablet excipients

Representative generic cyclobenzaprine tablets may contain:

• Lactose monohydrate or another filler
• Microcrystalline cellulose
• Pregelatinized starch or corn starch
• Croscarmellose sodium or sodium starch glycolate
• Colloidal silicon dioxide
• Magnesium stearate
• Hypromellose
• Titanium dioxide
• Pharmaceutical colorants

The most commercially relevant functions are tablet dilution, flow, lubrication, rapid disintegration, hardness control, and film-coating performance.

Cyclobenzaprine hydrochloride is generally suitable for conventional solid oral processing, but the product’s low-dose strengths create a content-uniformity challenge. A 5 mg tablet has a relatively small active load compared with the total tablet mass. Blend uniformity, segregation control, and low-shear lubrication are therefore more important than simply minimizing excipient cost.

Extended-release capsule excipients

Extended-release cyclobenzaprine capsules use multiparticulate technology rather than a conventional immediate-release tablet matrix. The formulation may include:

• Sugar spheres or inert starter cores
• Drug-layering binders
• Hypromellose or other film-forming polymers
• Ethylcellulose or another release-controlling polymer
• Talc
• Plasticizers
• Gelatin capsule shells
• Titanium dioxide and colorants

This architecture allows release control through coated pellets or beads. It also creates a larger manufacturing burden involving drug layering, coating uniformity, residual solvent control, capsule filling, and in-vitro release testing.

The excipient strategy for an extended-release product must be designed around dissolution robustness. Small changes in polymer grade, coating weight, pore former concentration, pellet size distribution, or curing conditions can alter the release profile. These changes can create bioequivalence risk even when the active ingredient and nominal dose remain unchanged.

Which excipient strategy is best for immediate-release cyclobenzaprine?

The strongest immediate-release strategy is a low-cost, high-robustness formulation that achieves rapid disintegration without compromising tablet strength or content uniformity.

Recommended formulation architecture

A practical platform may use:

1. Microcrystalline cellulose or a cellulose-based filler for compressibility.
2. Pregelatinized starch or crospovidone for disintegration and processing resilience.
3. Colloidal silicon dioxide for flow improvement.
4. Magnesium stearate at a controlled concentration and blending time.
5. A thin hypromellose film coat for identification, handling, and moisture protection.

The optimal system depends on the active’s particle size, bulk density, electrostatic behavior, and crystallinity. Excipients should be screened through design-of-experiments work focused on:

• Assay and content uniformity
• Tablet tensile strength
• Friability
• Disintegration time
• Dissolution across multiple pH conditions
• Blend segregation
• Lubrication sensitivity
• Stability under humidity stress

A formulation that matches the reference dissolution profile at one condition but becomes slow under high humidity may generate manufacturing losses and regulatory risk. Supplier qualification and lot-to-lot excipient consistency are commercially significant.

Cost-control opportunities

The generic immediate-release market rewards manufacturing efficiency more than premium excipient selection. Opportunities include:

• Direct compression where powder flow and compressibility permit
• Reduction of unnecessary coating weight
• Use of widely available compendial excipients
• Dual-purpose excipients that provide both binding and disintegration
• Standardized excipient platforms across 5 mg and 10 mg strengths
• High-speed compression with controlled dwell time
• Fewer supplier changes after regulatory approval

The lowest-cost formulation is not necessarily the most competitive. Tablet defects, dissolution failures, and supply interruptions can exceed the savings from a cheaper filler or lubricant.

What formulations are protected by cyclobenzaprine patents?

Cyclobenzaprine’s original small-molecule patent position is not the principal commercial barrier in the current U.S. market. The active ingredient has been genericized for many years, and immediate-release tablets are broadly available.

The historical Amrix extended-release product relied on formulation and controlled-release technology rather than a new chemical entity. Any relevant patent protection must be evaluated by product, jurisdiction, and Orange Book listing rather than inferred from the existence of the brand.

IP category	Current commercial significance
Original active-ingredient patents	Historical; not a practical barrier to ordinary generic entry
Immediate-release tablet patents	Limited strategic value where standard generic products are established
Extended-release formulation patents	Potentially relevant to release-controlled products, depending on live claims and listings
Method-of-use patents	Usually narrower than product patents and subject to carve-out analysis
Manufacturing patents	May affect specific pellet, coating, or process technologies
Excipient patents	Relevant only where a proprietary delivery system is used
Trade secrets	Potentially important for coating parameters, pellet processing, and scale-up

A patent analysis should use the FDA Orange Book, the patent owner’s filings, and national patent registers. The analysis must distinguish listed patents from expired patents, unlisted process patents, and patents that do not block a conventional immediate-release ANDA.

What is the Orange Book status of cyclobenzaprine?

Immediate-release cyclobenzaprine tablets are generally treated as mature generic products. The Orange Book remains the controlling source for listed patents, therapeutic-equivalence codes, reference listed drugs, and product marketing status.[2]

For a new immediate-release generic, the principal regulatory issue is usually abbreviated approval and bioequivalence rather than a novel patent barrier. For an extended-release product, the relevant questions are different:

• Which product is the reference listed drug?
• Are any formulation patents listed?
• Does the proposed product require a full in-vitro and in-vivo release comparison?
• Can the applicant use a paragraph IV certification?
• Is a section viii statement available for any method-of-use patent?
• Are the proposed strengths and dosing instructions consistent with the reference product?

Patent and exclusivity conclusions should be made from the current Orange Book record for the specific reference product. A generic applicant should not assume that the absence of an immediate-release barrier eliminates risk for extended-release beads or capsules.

When does cyclobenzaprine lose exclusivity?

Cyclobenzaprine immediate-release products lost meaningful market exclusivity long ago. The current commercial market is driven by generic competition, payer substitution, manufacturing economics, and distribution access.

The historical extended-release product had a later market entry and separate formulation considerations. Its commercial exclusivity and patent position are distinct from the immediate-release tablet market. A later entrant may still face technical or legal issues even where the underlying active ingredient is widely genericized.

Exclusivity type	Immediate-release cyclobenzaprine	Extended-release cyclobenzaprine
Chemical exclusivity	Expired historical protection	Expired or commercially ineffective for the active ingredient
Regulatory exclusivity	No material current barrier expected for standard generic tablets	Product-specific historical exclusivity may have applied
Formulation exclusivity	Limited for conventional tablets	More relevant for coated multiparticulates or controlled release
Current entry model	Standard ANDA	ANDA or potentially 505(b)(2), depending on product design
Primary risk	Price erosion and supply competition	Bioequivalence, release-control, and patent analysis

Which cyclobenzaprine dosage forms offer the best commercial opportunity?

Orally disintegrating tablets

An orally disintegrating tablet could address patients who have difficulty swallowing conventional tablets. The formulation would need rapid disintegration, acceptable taste, low friability, and adequate moisture protection.

Potential excipient technologies include:

• Mannitol for mouthfeel and cooling sensation
• Crospovidone or low-substituted hydroxypropyl cellulose for rapid disintegration
• Sucralose or another sweetener
• Flavor systems
• Silica for flow
• Taste-masking polymers or coated drug particles

Taste masking is a central technical issue. Cyclobenzaprine’s pharmacology and low dose may permit a small tablet, but the active must be evaluated for bitterness and oral residue. An ODT could be submitted as a generic only if it matches the reference product’s requirements. A materially different dosage form may require a 505(b)(2) strategy.

Oral liquid

An oral solution or suspension could target patients with dysphagia, institutional care needs, and dose flexibility. Key excipient issues include:

• Solubility and pH control
• Preservative selection
• Microbial limits
• Viscosity
• Sedimentation control for suspensions
• Sugar-free or low-sugar presentation
• Container-closure compatibility
• Accurate dosing devices

A liquid product may have higher development and distribution costs than tablets. It can still command a commercial position in long-term-care, specialty pharmacy, pediatric-adjacent, or swallowing-impaired populations, subject to labeling restrictions and clinical appropriateness.

Sprinkle capsule

A sprinkle capsule containing immediate-release or modified-release pellets could improve administration for patients unable to swallow tablets. The product would require robust labeling concerning opening the capsule, mixing with food, chewing restrictions, and dose recovery.

This dosage form could have more defensible formulation know-how than a conventional tablet. It also creates greater manufacturing complexity and may require a separate bioequivalence strategy.

Extended-release formulation

Extended-release cyclobenzaprine offers the clearest technical differentiation, but it has the highest development risk. Important variables include:

• Pellet size distribution
• Drug-layering efficiency
• Polymer coating weight
• Coating defects
• Dose-dumping resistance
• Food effect
• Alcohol interaction
• Storage stability
• In-vitro/in-vivo release correlation

The commercial value depends on whether prescribers and payers view once-daily dosing as sufficiently valuable to offset generic competition and a potentially higher price.

Topical and transdermal products

Topical cyclobenzaprine could be positioned as a local-delivery product, but it would not be a routine generic substitution for an oral tablet. Skin permeation, systemic exposure, local tolerability, dose uniformity, and clinical efficacy would require a separate development program.

A topical product would likely need a 505(b)(2) pathway or another regulatory route based on the extent of formulation and clinical differences. Its commercial opportunity would depend on demonstrating a meaningful benefit, not merely changing the route of administration.

How can excipients support a paragraph IV or 505(b)(2) strategy?

A conventional immediate-release generic typically relies on an ANDA and must demonstrate pharmaceutical equivalence and bioequivalence. Excipients should therefore remain within a well-characterized, regulatory-compatible framework.

A 505(b)(2) strategy may be appropriate for:

• A new dosage form
• A modified release profile
• A liquid formulation
• An ODT
• A transdermal or topical product
• A product with a different dosing schedule
• A formulation with a clinically supported administration advantage

The commercial benefit of a 505(b)(2) product is potential differentiation. The cost is a larger evidence package, including clinical pharmacology and possibly clinical efficacy or safety data.

Excipient changes alone do not create a defensible product. The value must come from a measurable product attribute, such as improved administration, consistent exposure, reduced dosing frequency, or a clinically relevant patient-use advantage.

What generic entry risks exist for cyclobenzaprine?

Paragraph IV challenges

For immediate-release tablets, a paragraph IV challenge may have limited value if the relevant patents are expired, absent, or commercially weak. For extended-release products, a paragraph IV filing could be more relevant where a live formulation or release-control patent is listed.

Potential risks include:

• Failure to identify all listed patents
• Inadequate claim construction
• Infringement of pellet-coating or release-control claims
• A formulation that falls within a broad controlled-release claim
• Litigation-triggered launch delay
• At-risk launch exposure
• Failure to obtain a favorable 30-month-stay outcome

Bioequivalence risk

The main technical risk for immediate-release tablets is usually manageable. It increases when the applicant introduces:

• A novel disintegrant system
• Taste-masked particles
• A high-viscosity liquid vehicle
• A modified-release matrix
• Multiparticulate capsules
• A new food-effect profile

Manufacturing and IP barriers

Manufacturing barriers are more important than active-ingredient patent barriers. They include:

• Reliable low-dose blending
• Pellet drug layering
• Uniform polymer coating
• Controlled release after scale-up
• Supply of pharmaceutical-grade excipients
• Proprietary coating equipment
• Validated container-closure systems
• Stability under hot and humid conditions

A formulation may be legally open but commercially difficult to manufacture at acceptable yield.

Which companies are challenging or supplying cyclobenzaprine?

The generic market includes major U.S. and international manufacturers, contract manufacturers, and private-label suppliers. Market participation changes by strength, dosage form, wholesaler contract, and product discontinuation status.

Commercial competition is usually based on:

• Wholesale acquisition cost
• Rebate and wholesaler terms
• Backorder performance
• FDA compliance history
• Manufacturing redundancy
• Product availability across 5 mg and 10 mg strengths
• Ability to supply institutional customers

For a new entrant, a dependable supply position may have greater value than a minor excipient innovation. A second-source strategy is especially important because tablet excipients, capsule shells, film-coating materials, and specialty polymers can create separate supply risks.

How does cyclobenzaprine compare with competing muscle relaxants?

Cyclobenzaprine competes with generic products such as tizanidine, baclofen, methocarbamol, and carisoprodol. The competitive comparison is driven by adverse-effect profiles, dosing frequency, abuse concerns, prescriber familiarity, payer coverage, and formulation availability.

Product	Common commercial differentiation	Excipient opportunity
Cyclobenzaprine	Established use; immediate- and extended-release history	ODT, liquid, sprinkle, cost-efficient tablets
Tizanidine	Immediate- and modified-release products	Modified release and dose flexibility
Baclofen	Multiple dosage forms and chronic-use positioning	Liquid, pediatric-compatible administration
Methocarbamol	Multiple strengths and established generic supply	High-throughput tablet platform
Carisoprodol	Abuse and dependence concerns	Limited opportunity without major safety differentiation

Cyclobenzaprine’s long half-life and sedating, anticholinergic profile may limit the value of aggressive dosing convenience claims. Product development should focus on administration and adherence rather than implying improved safety without clinical evidence.

What licensing deals could create value?

Licensing opportunities are most plausible in four areas:

1. Controlled-release pellet technology.
2. Taste-masking and orally disintegrating platforms.
3. Pharmaceutical liquid vehicles and dose-delivery systems.
4. Contract manufacturing with validated coating and multiparticulate capability.

An asset owner could license a cyclobenzaprine formulation to a generic company with established payer access. A generic manufacturer could license a delivery platform rather than acquire a compound patent estate.

The strongest deal structures would link royalties to measurable commercial value, such as net sales of a once-daily product, approval milestones, or supply commitments. A license based only on the use of standard excipients would have limited bargaining power.

What is the revenue exposure and market outlook for cyclobenzaprine?

Revenue exposure is concentrated in volume rather than high unit economics. Immediate-release tablets are vulnerable to price erosion because multiple suppliers can use similar excipient systems and manufacturing processes.

Higher-value opportunities may arise from:

• Institutional and long-term-care supply
• Consistent national availability
• Low-dose or flexible-dose liquids
• ODT products for swallowing-impaired patients
• Once-daily modified-release products
• Authorized private-label arrangements
• Specialty pharmacy distribution
• International markets with fewer suppliers

A commercial model should assess net price, annual prescription volume, expected generic entrants, manufacturing yield, regulatory filing costs, and wholesaler deductions. Product differentiation without payer acceptance will not protect margins.

What geographic markets offer the best opportunity?

The United States has the largest regulatory and commercial infrastructure but also the highest generic competition. Europe, Canada, Australia, Latin America, and selected Asian markets may offer opportunities where:

• Extended-release products are absent or under-supplied
• Liquid or ODT presentations are limited
• Local generic competition is narrower
• Dossier bridging is manageable
• Local manufacturing or licensing is commercially preferred

Patent clearance must be conducted separately in each jurisdiction. Regulatory status, reference-product availability, excipient acceptability, labeling rules, and pharmacopoeial requirements vary by market.

Key Takeaways

• Cyclobenzaprine is a mature genericized drug with limited conventional patent leverage.
• Immediate-release tablets are the lowest-risk development target but offer limited margin protection.
• The best excipient strategy emphasizes content uniformity, rapid disintegration, manufacturability, and low cost.
• ODT, oral liquid, sprinkle capsule, and extended-release products offer the strongest differentiation potential.
• Multiparticulate extended-release products have higher technical and patent risk than standard tablets.
• A 505(b)(2) pathway may be appropriate for materially different dosage forms or delivery systems.
• Manufacturing reliability, excipient supply, and payer access are more important commercial barriers than the original active-ingredient patent estate.
• Licensing value is concentrated in delivery platforms, taste masking, controlled release, and validated manufacturing capability.

FAQs

Can cyclobenzaprine be reformulated as an orally disintegrating tablet?

Yes. An ODT would require rapid disintegration, acceptable taste, moisture protection, and a regulatory strategy consistent with the proposed reference product or 505(b)(2) pathway.

Which excipients are most important for cyclobenzaprine taste masking?

Mannitol, sweeteners, flavors, polymeric coating systems, and coated drug particles are common options. The best choice depends on bitterness, dose, tablet size, and dissolution requirements.

Is an extended-release cyclobenzaprine product commercially defensible?

Potentially, but the product must demonstrate a meaningful dosing or adherence advantage. Release-control performance, food effect, manufacturing complexity, and patent status create higher development risk.

Does a new cyclobenzaprine excipient system create patent protection?

Not by itself. Patent value requires a novel and non-obvious formulation, delivery system, manufacturing process, or clinically relevant product characteristic with enforceable claims.

Would a cyclobenzaprine liquid require clinical studies?

The study requirements depend on the formulation, regulatory pathway, reference product, and extent of the proposed change. A conventional generic may follow an ANDA framework, while a materially different liquid may require a 505(b)(2) application and additional clinical pharmacology work.

References

1. U.S. Food and Drug Administration. (2023). Cyclobenzaprine hydrochloride tablets prescribing information. FDA and DailyMed labeling database.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

4. U.S. Food and Drug Administration. (2017). Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.

5. U.S. Food and Drug Administration. (2022). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.

6. U.S. Food and Drug Administration. (2023). Amrix prescribing information. FDA and DailyMed labeling database.